Risk Assessment for Excipients for Enhanced Patient Safety - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Risk Assessment for Excipients for Enhanced Patient Safety
The author describes key considertions for a complete risk-assessment model and provides insight into a pending IPEC guideline in this area.


Pharmaceutical Technology
Volume 35, pp. s29-s33

An excipient-product risk assessment is performed by the excipient manufacturer that has expertise and knowledge in excipient manufacture and inherent characteristics. For raw materials:

  • Physical and chemical characteristics are typically unique to an excipient regardless of the manufacturing location
  • Type, source, and history of supply for raw materials used in excipient manufacturing may be common to a given excipient
  • Excipients can be made from different sources and/or materials sourced from different regions with associated risk.

Risk-assessment outcomes may differ for a specific excipient based upon manufacturer and location. The differences in outcomes increase exponentially when the variables associated with excipient manufacturing are considered (see Figure 2). The same excipient made by the same process methodology can have different risk-assessment outcomes depending on variables, such as:

  • Type of equipment used
  • Facility floor plan
  • Physical location of the manufacturing plant
  • Dedicated versus multiple use operations
  • Conveying methodology
  • Open versus closed systems
  • Choice of processing aids
  • Recycle and recovery in process
  • Robustness of the engineering design
  • Process cleaning operations


Figure 2: Excipient risk-assessment categories.
Effective implementation of excipient GMPs helps equalize these differences to an acceptable level of potential risk. However, a true and complete risk assessment for the realization of an excipient must be unique to a given manufacturing location.

Supply-chain concerns

Risk-assessment outcomes can also change over time due to changes in GMP expectations and to the manufacture of the excipient. For example, risk assessment for excipient storage and distribution can be generalized, but also depends on the particular circumstances. An excipient that is susceptible to degradation or modification during storage or transport, for example, has more potential for failure in than a stable excipient. Good distribution practices (GDP) require adequate control and monitoring of storage conditions for excipients susceptible to environmental conditions. While GDP conformance lowers risk during storage and distribution of an excipient, poor storage practices or distribution methods may heighten the risk associated with an excipient. For example:

  • Using dedicated vessels or single-use containers versus allowing back hauls or reusable containers
  • Short-direct distribution paths minimize the risk of tampering or contamination during transfer versus a longer route that may offer greater opportunity
  • Trace contaminants introduced from packaging, storage, or transfer may react slowly over time with the excipient
  • Changes in ownership, repackaging, and relabeling operations bring unique opportunities to adversely affect the quality or the reported characteristics and increases the risk of mislabeling.

These acts may result in the same excipient having different risk levels based on the differences in distribution. Excipient manufactures whose primary sales outlet for excipients is through distribution companies do not always have a sufficient view of the supply chain necessary to perform adequate risk assessments and likewise the excipient users may not have a clear view of the supply chain beyond their immediate supplier. This lack of clarity in the supply chain creates a knowledge gap that in and of itself increases risk in terms of potential adulteration or contamination. Product testing is an impractical remediation for unknown gaps in the supply chain because one often does not know what tests to perform. It's crucial to know and understand the excipient's full supply and distribution chain.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here